Joshua Oaks, MD
Internal Medicine · Bountiful, UTNPI 1205221405
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 1,082 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.9% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,082 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Amgen$1K
- AbbVie$1K
- AstraZeneca$1K
- Boehringer Ingelheim$974
- Astellas Pharma US Inc$947
- plus $9K from 54 others
Across 53 payments — averaging $18,041 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$652K
- Romark Laboratories, LC$190K
- Novo Nordisk AS$90K
- Alnylam Pharmaceuticals Inc.$24K
What the payments were for
- Consulting fees$3002%
- Food & beverage$15,86597%
- Education$2742%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,439 in reported general payments places this provider in the 95th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 243 | $338,629 |
| OzempicSemaglutide | 141 | $200,786 |
| JardianceEmpagliflozin | 81 | $134,687 |
| XareltoRivaroxaban | 86 | $96,172 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 58 | $85,663 |
| MounjaroTirzepatide | 33 | $57,268 |
| FarxigaDapagliflozin Propanediol | 47 | $55,557 |
| MyrbetriqMirabegron | 61 | $47,491 |
| TrulicityDulaglutide | 20 | $40,071 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $35,899 |
| RybelsusSemaglutide | 18 | $35,407 |
| JanuviaSitagliptin Phosphate | 31 | $29,223 |
| Repatha SureclickEvolocumab | 16 | $24,406 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $23,892 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $20,644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,458 | $338,629243 claims |
| Novo NordiskOzempic, Rybelsus | $577 | $236,193159 claims |
| Boehringer IngelheimJardiance | $974 | $134,68781 claims |
| Lilly USA, LLCMounjaro, Trulicity | $906 | $97,33853 claims |
| Johnson & JohnsonXarelto | $862 | $96,17286 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $505 | $85,66358 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,197 | $79,45071 claims |
| Astellas Pharma US IncMyrbetriq | $947 | $47,49161 claims |
| MerckJanuvia, Dulera | $672 | $34,45444 claims |
| GSKTrelegy Ellipta | $382 | $20,64411 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $58 | $8,833749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Bountiful
- Lisani EstopinanBountiful$6K
- Scott SouthworthBountiful$6K
- Val HansenBountiful$5K
- Willard DereSalt Lake City$4.7M
- Kenneth SchaecherWest Valley City$333K
- Steven CallSpringville$178K
- James ChamberlainSalt Lake City$106K
- Alexander PastuszakSalt Lake City$87K
- Zameer AbedinSalt Lake City$83K
- Kashif MemonVernal$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.